The primary objective of the study is to explore the role of inflammation in the anterior chamber on endothelial cell loss in patients implanted with iris-fixated pIOLs. The secondary objective is to identify whether there is a correlation between…
ID
Source
Brief title
Condition
- Anterior eye structural change, deposit and degeneration
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameter is difference in pro-inflammatory cytokine levels -
among others MMP9- between patients undergoing a pIOL explantation in
combination with a cataract surgery compared to pro-inflammatory cytokine
levels of patients only undergoing cataract surgery in aqueous humour.
Secondary outcome
The secondary parameter is the correlation between cytokines in aqueous humour
and their expression in tears.
Background summary
The number of highly myopic patients is increasing. Especially in East and
Southeast Asia, up to 90% of adolescents are currently myopic. Long-term
treatment of high myopia can be obtained by three types of surgery: laser
refractive surgery, phakic intraocular lens (pIOL) implantation, and refractive
lens exchange Implantation with a pIOL is the preferred treatment for high
myopes, resulting in increasing patient numbers implanted due to the increasing
numbers of patients with high myopia.
Long-term results show that implantation of a pIOL induces an accelerated
decrease in corneal endothelial cells (EC). Although some risk factors for
increase EC loss have been identified, the underlying mechanism is currently
unknown. It is hypothesized that the aqueous flow in the anterior segment of
the eye (i.e. anterior chamber) is disturbed, causing an altered nutritional
flow in the anterior chamber. Another hypothesis is that the pIOL causes
chronic subclinical inflammation in the anterior chamber resulting in increased
EC loss. Currently there is insufficient proof to confirm or reject either
hypothesis. If one of these hypotheses can be confirmed, it is likely to
induces significant changes in clinical practice.
Study objective
The primary objective of the study is to explore the role of inflammation in
the anterior chamber on endothelial cell loss in patients implanted with
iris-fixated pIOLs. The secondary objective is to identify whether there is a
correlation between biomarkers in aqueous humour and biomarkers in tears, both
related to the accelerated progression of EC loss.
Study design
Two strategies are incorporated in the design of this study. The first part
will retrospectively evaluate EC loss in patients with iris-fixated (IF) phakic
intraocular lenses (pIOLs). The second part is prospective and will compare EC
measurements, cytokines in aqueous humour and in tears from patients scheduled
for IF-pIOLs explantation and compare them to patients with routine cataract
surgery.
Study burden and risks
In both groups preoperatively, tears will be collected using a Schirmer strip.
Schirmer strips are small paper strips which are placed behind the lower
eyelid, in the inferior fornix of the eye to absorb tear fluid. Tear collection
is non-invasive without risk for complications. During surgery, aqueous humour,
the phakic intraocular lens, and the lens capsule, will be collected, which
will not increase the burden for the patient, nor the risk of an infection.
P Debyelaan 25
Maastricht 6229HX
NL
P Debyelaan 25
Maastricht 6229HX
NL
Listed location countries
Age
Inclusion criteria
Age over 18 ,
Cataract in one or both eyes, or indication for phakic intra-ocular lens
explantation (Artisan or Artiflex lenses)
Informed and having given informed consent.
Exclusion criteria
• Insufficient understanding of the Dutch language to comply with study
procedures
• Inability to complete follow-up or comply with study procedures
• Non-routine cataract surgery (e.g., cataract surgery combined with another
ocular procedure - other than pIOL explantation -, cataract surgery under
general anaesthe-sia)
• Cognitive or behavioral conditions that might interfere with surgery
• Patients with ocular comorbidities such as: diabetes with vision threatening
diabetic retinopathy or diabetic macular edema, glaucoma (or IOP >24 mmHg),
keratitis, keratoconus, keratopathy, corneal dystrophy, and uveitis.
• Women who are pregnant or nursing their child
• Immune-compromised patients (e.g., systemic corticosteroid use, leukaemia)
• Factors that increase the risk of complicated surgery:
o Previous ocular surgery (for the control group)
o Previous perforating or blunt eye trauma
o Eye, adnexal, or anatomical abnormalities (including pseudoexfoliation
syn-drome)
o Lens luxation or iridodonesis
o Cataract nigrans, posterior polar cataract
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL70342.068.19 |